Literature DB >> 10588092

Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension.

G Mancia1, R Dell'Oro, C Turri, G Grassi.   

Abstract

Blood pressure remains poorly controlled in the hypertensive population due in large part to low or unsatisfactory patient compliance. Clinical studies that incorporate an intentionally missed dose have been designed to evaluate the impact of poor patient compliance on the effectiveness of antihypertensive medications. In these studies, ambulatory blood pressure monitoring is continued throughout the dosing interval and beyond in order to determine when systolic and diastolic blood pressure increase into the hypertensive range. In an 8-week, randomized, double-blind, placebo-controlled trial in patients with mild-to-moderate hypertension, the antihypertensive effects of candesartan cilexetil 16 mg were maintained after a missed dose, whereas systolic and diastolic blood pressure increased toward baseline levels after a missed dose of losartan 100 mg. Candesartan cilexetil provided a significantly greater reduction in sitting systolic (p = 0.004) and diastolic blood pressure (p = 0.008) than losartan when measured 48 hours after the last dose. Moreover, the homogeneity of antihypertensive effects was greater after candesartan cilexetil than losartan based on calculation of the smoothness index from ambulatory systolic and diastolic measurements during the first 24-hour period after dosing and during the 12-hour period after the missed dose. These results demonstrate that missing or delaying a dose of candesartan cilexetil has less impact on antihypertensive efficacy than missing or delaying a dose of losartan.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588092     DOI: 10.1016/s0002-9149(99)00731-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.

Authors:  W J Elliott
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

2.  Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Authors:  S Oparil; D Williams; S G Chrysant; T C Marbury; J Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

Review 3.  Class effects and labeling of antihypertensive drugs.

Authors:  Thomas G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-03       Impact factor: 3.738

4.  The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension.

Authors:  Robert A Phillips; Robert A Kloner; Richard H Grimm; Myron Weinberger
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jan-Feb       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.